Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty
Provided By PR Newswire
Last update: Jun 25, 2025
*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market
Exclusive License from U.S. Department of Veterans Affairs to Advance GDNF-Based Therapy for Obesity and Fatty Liver Disease
Read more at prnewswire.comNASDAQ:SILO (6/26/2025, 12:25:52 PM)
0.6458
+0 (+0.44%)
NASDAQ:HOTH (6/26/2025, 12:25:10 PM)
1.1703
-0.02 (-1.66%)
Find more stocks in the Stock Screener
SILO Latest News and Analysis
17 days ago - ChartmillGet insights into the top gainers and losers of Monday's pre-market session.The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
